iCardiac Technologies, Inc., is the industry’s most innovative core laboratory for cardiac safety and respiratory services. We have introduced multiple breakthrough innovations to the cardiac safety industry, including our High Precision QT and Early Precision QT methodologies. iCardiac’s precision-optimizing cardiac safety assessment methodology has set a new standard for precision and accuracy in all phases of clinical trials. We have run some of the largest global respiratory studies that have ever occurred in the industry, and our unique platform ensures that subjects are not inappropriately included or excluded from studies. iCardiac serves 8 of the top 10 global pharma, as well as numerous small and mid-sized pharma and biotech companies. Our team members are active contributors on several FDA working groups that are advancing the field of drug safety.